
    
      The hypothesis is that co-administrationof colesevelam plus sitagliptin results in a greater
      reduction in HbA1c compared to colesevelam HCl treatment by

        1. improving the effects of colesevelam on fasting glucose metabolism

        2. improving the effects of colsevelam on postprandial glucose metabolism
    
  